Johnson & Johnson Nanobiotix S.A. Call Options Transaction History
Johnson & Johnson
- $293 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBTX
# of Institutions
17Shares Held
6.5MCall Options Held
0Put Options Held
0-
Perceptive Advisors LLC New York, NY266KShares$1.11 Million0.03% of portfolio
-
Black Rock Inc. New York, NY239KShares$994,2730.0% of portfolio
-
Old Mission Capital LLC48.5KShares$201,6510.0% of portfolio
-
Jane Street Group, LLC New York, NY23.3KShares$96,8570.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny13.5KShares$55,9600.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $145M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...